This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. In a brief statement , the Belgian Competition Authority alleged that Roche offered financial incentives to hospitals between 2017 and 2020 to deter them from considering competitive bids from other pharmaceutical companies that could supply similar medicines.
Half of every dollar spent on medicines goes to entities that don’t make medicine—like pharmacy benefit managers (PBMs) and insurers who are aggressively consolidating their control over health care and hospitals, clinics and for-profit pharmacies in the 340B markup program. As entities in the supply chain that don’t make medicine are increasingly using medicines to subsidize other parts of their business, patients and employers face increasing costs and barriers to accessing c
Day or night, Marc Cohen, a major donor to Dana-Farber Cancer Institute, had a direct line to one of its leading oncologists. No question was too big or too small, and almost no hour was off limits for a consultation. Cohen and his doctor, Kenneth C. Anderson, exchanged hundreds of emails and texts over two decades about Cohen’s disease, multiple myeloma, a rare and incurable blood cancer that is Anderson’s specialty.
Introduction In todays competitive pharmaceutical landscape, marketing strategies must evolve to meet changing customer expectations. Are you still relying on traditional marketing tactics, or have you embraced a more dynamic, omnichannel marketing approach? With healthcare providers (HCPs) and patients engaging across multiple digital and offline touchpoints, pharma brands that fail to adapt risk losing valuable market share.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning! And happy St. Patrick’s Day. I grew up on the south shore of Boston, around what some call an “Irish riviera” — an area with a high proportion of families with Irish heritage, mine included.
In a recent report, the U.S. Federal Trade Commission released an update on patent settlements between brand-name and generic drug makers, but for the first time, mentioned a maneuver used by these companies that may raise a different type of antitrust concern. These settlements can be traced to a law passed 40 years ago that was designed to speed the entry of lower-cost generics to the marketplace.
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! We’re just a few days out from STAT’s Breakthrough Summit East !
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
This investigational medicine is stated to be the first ribonucleic acid (RNA) editing development candidate from the companys Oligonucleotide Promoted Editing of RNA (OPERA) platform. Korro Bio chief medical officer Kemi Olugemo said: Receiving orphan drug designation from the FDA underscores the growing need for new treatments for patients living with AATD.
Kimberly A. Beer Joins the National Health Council as Senior Vice President, Policy and External Affairs (PDF) Contact For Immediate Release Jennifer Schleman jschleman@nhcouncil.org (WASHINGTON, DC, March 17, 2025) The National Health Council (NHC) welcomes Kimberly A.
Study results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant in treating certain blood cancers.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
The National Pharmacy Association (NPA) has advised its members in England to reduce their opening hours, as a funding deal for the sector has still not yet been announced. This could see NPA pharmacies give notice from 1 April that they will reduce their opening hours to core contractual minimums. Reduced opening hours could then […] The post NPA tells pharmacies to reduce hours as April looms with no contract yet appeared first on The Pharmacist.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
mAbTree Biologics has signed an exclusive co-development and commercialisation partnership with Shilpa Biologicals (a fully owned subsidiary of Shilpa Medicare) for its novel biologic asset [a checkpoint inhibitor] for immuno-oncological applications. Under the terms of the strategic agreement, Shilpa Biologicals will support both development including clinical studies as well as long-term commercial supply with GMP manufacturing.
The British drugmaker is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer as well as autoimmune conditions.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, comments on how he envisions automation in the CAR-T manufacturing space playing a role in improving efficiency, reducing costs, and ultimately, expanding patient access.
The pharma will acquire Araris Biotech to gain access to a trio of preclinical ADCs and a linking technology Araris claims is superior to conventional platforms.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
236 
Let's personalize your content